DOSES STUDIED // µg/kg · ROUTE · HALF-LIFE
CJC-1295 Ipamorelin Dosage as Studied in the Research Literature
What was administered, to which species, by which route, at which dose — logged from the studies. No human protocol, no recommendation.
Read this first
This page logs CJC-1295 Ipamorelin dosage only as it appears in published studies — what researchers gave to people or animals, how, and for how long. It is not a protocol and not advice. There is no recommended human dose here, because neither peptide is approved and the fixed blend was never trialed. Numbers appear strictly as "studied at X µg/kg in [species] by [route]."
The headline to carry: the two halves last very different amounts of time. CJC-1295 with DAC stays active for days because it locks onto a blood protein; the no-DAC form and ipamorelin last minutes to a couple of hours. That mismatch is the single most important fact for understanding why a dosing schedule for one half does not transfer to the other.
Cjc 1295 ipamorelin dosage: the figures from the studies
The human cjc 1295 ipamorelin dosage figures come from the CJC-1295 side. In Phase 1 pharmacokinetic studies, CJC-1295 with DAC was given to healthy adults at 30 to 90 µg/kg subcutaneously, single and ascending doses [1][8]. At 60 or 90 µg/kg as a single subcutaneous injection, basal GH rose about 7.5-fold while pulsatility was preserved [8]. These were controlled research doses measured for pharmacokinetics — not a maintenance regimen and not transferable to community use.
For ipamorelin, the published doses are almost entirely from animal work: roughly 100 µg/kg three times daily in rodent bone studies, 0.5 mg/kg/day for bone mineral endpoints, and 0.01 to 1 mg/kg intravenously for gut-motility work, with around 1 µg/kg plateauing the GH response in rodent models. No validated human pharmacokinetic dose for ipamorelin has been published. There is no peer-reviewed human dosing study of the pre-mixed combination at all.
Cjc 1295 dac: why the DAC form is dosed less often
The cjc 1295 dac form is the long-acting one. DAC stands for Drug Affinity Complex: a chemical group on the peptide covalently bonds to Cys34 of serum albumin, a protein abundant in blood, turning the peptide into a slow-release depot. In rats this produced roughly a four-fold rise in GH area-under-the-curve and albumin-bound peptide detectable beyond 72 hours [5]; in humans a single dose sustained elevated GH for six or more days and IGF-1 for nine to eleven days [1]. Because the effect lasts days, research dosing of the DAC form is infrequent by design — its whole purpose is to avoid frequent injection. Its half-life in humans is on the order of six to eight days.
Mod grf 1-29: the short-acting, no-DAC counterpart
Mod grf 1-29 is CJC-1295 without DAC — the same modified GHRH(1-29) fragment, minus the albumin anchor. It produces a short, pulsatile GHRH signal rather than a multi-day plateau, with a half-life on the order of minutes to about 30 minutes, because dipeptidyl peptidase-IV rapidly cleaves GHRH-type peptides [14]. No formal standalone human pharmacokinetic study of Mod GRF (1-29) exists; research protocols have modelled it at roughly 100 to 200 µg per injection. The practical distinction: the DAC form gives a sustained background, while Mod GRF (1-29) gives a brief spike meant to mimic a natural GH burst. Confusing the two is the most common error in reading this literature, and it changes the entire exposure profile.
Routes, stability, and the human-data gap
Routes studied are subcutaneous and intravenous, plus continuous subcutaneous infusion by osmotic minipump and intranasal delivery in rodent pharmacokinetic work. On handling: lyophilised (freeze-dried) peptide is stable frozen for long periods; once reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative), aqueous peptide is kept refrigerated and degrades over weeks via asparagine deamidation, with degradation products markedly less potent. This is standard laboratory-handling context only.
The human-data gap is the headline limitation. CJC-1295 with DAC reached Phase 2 before development was discontinued; ipamorelin was investigated, including for postoperative ileus, but never approved. There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295/ipamorelin combination itself, so any "dose" for the blend is extrapolation from each component's separate literature plus general synergy data — not a studied figure.
Extrapolation, and who is allowed to do it
Someone has to close the gap the studies left open
If every blend dose is extrapolation from two separate literatures, the question is who performs the extrapolation and who reviews the result. Self-directed use answers both with the same person. Prescription peptide therapy splits them: a clinician sets the starting protocol, reads the IGF-1 response, and changes it. Promise Peptides (mypromise.com) is a licensed telehealth practice whose clinicians prescribe CJC-1295/ipamorelin as a compounded preparation on that model. This page still declines to name a human dose, and the missing pharmacology study named above stays missing — supervision is a statement about oversight, not a substitute for the trial.